
Physicians are sometimes reluctant to initiate guideline‐directed therapy in patients with heart failure and reduced ejection fraction (HFrEF) due to concerns about adverse events. The study explored the risk of hypotension, volume depletion, and acute kidney injury (AKI) on sodium-glucose cotransporter 2 (SGLT2) inhibitors in HFrEF populations. Sodium-glucose cotransporter 2 inhibitor therapy is not associated with a clinically relevant risk of hypotension and volume depletion. Its use reduces the risk of AKI. This analysis supports current guideline recommendations on the early use of SGLT2 inhibitors.
Like
Save
Share